ConforMIS (NASDAQ: CFMS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare ConforMIS to related businesses based on the strength of its earnings, dividends, valuation, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares ConforMIS and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ConforMIS $79.90 million -$57.58 million -2.46
ConforMIS Competitors $1.67 billion $207.58 million 81.73

ConforMIS’s rivals have higher revenue and earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares ConforMIS and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ConforMIS -72.70% -76.88% -51.42%
ConforMIS Competitors -101.23% -92.70% -30.32%

Volatility & Risk

ConforMIS has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500. Comparatively, ConforMIS’s rivals have a beta of 0.96, meaning that their average share price is 4% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for ConforMIS and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConforMIS 0 3 2 0 2.40
ConforMIS Competitors 109 728 1025 10 2.50

ConforMIS presently has a consensus price target of $6.13, indicating a potential upside of 85.61%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.76%. Given ConforMIS’s higher possible upside, analysts plainly believe ConforMIS is more favorable than its rivals.

Institutional & Insider Ownership

36.0% of ConforMIS shares are held by institutional investors. Comparatively, 54.9% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 9.6% of ConforMIS shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ConforMIS rivals beat ConforMIS on 8 of the 12 factors compared.

About ConforMIS

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.